Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY) Sees Significant Increase in Short Interest

Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY) saw a significant growth in short interest during the month of July. As of July 15th, there was short interest totaling 76,340 shares, a growth of 116.4% from the June 30th total of 35,280 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average daily trading volume, of 93,500 shares, the days-to-cover ratio is presently 0.8 days.

Otsuka Price Performance

Otsuka stock traded up $0.27 during trading hours on Wednesday, hitting $35.07. 9,569 shares of the company traded hands, compared to its average volume of 39,720. The firm has a market cap of $37.67 billion and a P/E ratio of 14.80. The company has a quick ratio of 1.67, a current ratio of 2.17 and a debt-to-equity ratio of 0.05. The firm’s 50-day simple moving average is $34.23 and its two-hundred day simple moving average is $33.43. Otsuka has a 1-year low of $23.67 and a 1-year high of $37.52.

Otsuka (OTCMKTS:OTSKY) last released its quarterly earnings results on Tuesday, April 28th. The company reported $0.59 EPS for the quarter, topping analysts’ consensus estimates of $0.43 by $0.16. The company had revenue of $3.96 billion for the quarter, compared to the consensus estimate of $3.78 billion. Otsuka had a net margin of 15.01% and a return on equity of 12.33%. As a group, analysts forecast that Otsuka will post 1.96 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Zacks Research upgraded shares of Otsuka from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 31st. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold”.

Otsuka Company Profile

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.